| We participate in medicine supply committees. | HIV
> HIV | Regulatory partnership
> Working with regulatory bodies | 5,000 | Local | Sometimes | 119013267866 |
| We maintain ongoing dialogue with Cofepris [Comisión Federal para la Protección contra Riesgos Sanitarios – Federal Commission for Protection against Sanitary Risks], the CSG [Consejo de Salubridad General – General Health Council], and the Ministry of Health [Mexico]. | Rare
> Rare diseases: most types | Regulatory partnership
> Working with regulatory bodies | 1,000 | National | Regularly | 119074943493 |
| 95% of the patients who comprise our target population access care through public health services. As an organisation, we have participated in the development of several clinical care guidelines. | Not specified
> Not specified | Regulatory partnership
> Involvement with clinical guideline-setting bodies | 100 | National | Regularly | 119063173812 |
| Meetings have taken place with authorities, primarily within the legislative sphere. | Transplants
> Transplants: most | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 100 | Regional | Rarely | 119037030189 |
| We participate in forums with authorities, representing the patient voice. | Rare
> Rare disorders: genetic | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 100 | National | Sometimes | 119074314899 |
| We maintain ongoing dialogue with Cofepris [Comisión Federal para la Protección contra Riesgos Sanitarios – Federal Commission for Protection against Sanitary Risks], the CSG [Consejo de Salubridad General – General Health Council], and the Ministry of Health [Mexico]. | Rare
> Rare diseases: most types | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 1,000 | National | Regularly | 119074943493 |
| We maintain ongoing dialogue with Cofepris [Comisión Federal para la Protección contra Riesgos Sanitarios – Federal Commission for Protection against Sanitary Risks], the CSG [Consejo de Salubridad General – General Health Council], and the Ministry of Health [Mexico]. | Rare
> Rare diseases: most types | Impacting policy and legislation
> Influence healthcare policy and legislation | 1,000 | National | Regularly | 119074943493 |
| Through forums and congresses. | Cancer
> Cancer: most types | Impacting policy and legislation
> Participate in public hearings and consultations | 1,000 | National | Rarely | 119013346537 |
| … The Federation takes part in meetings, consultations, and collaborative projects aimed at strengthening timely access to medicines and innovative therapies for the community. | Bleeding
> Haemophilia | Impacting policy and legislation
> Participate in public hearings and consultations | 1,000 | National | Sometimes | 119076498939 |
| We have agreements in place with a number of pharmaceutical companies to provide our patients with preferential pricing. | Cardiovascular
> Cardiovascular & heart conditions | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 1,000 | National | Sometimes | 119020507827 |
| Pharmaceutical manufacturers operated medication discount programmes, though these were discontinued in mid-2025. | Cancer
> Cancer: blood | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 100 | National | Regularly | 119072892669 |
| We have agreements in place with a number of pharmaceutical companies to provide our patients with preferential pricing. | Cardiovascular
> Cardiovascular & heart conditions | Pricing and affordability advocacy
> Tracking and monitoring drug pricing/drug shortages | 1,000 | National | Sometimes | 119020507827 |
| We participate in selection, procurement, and supply shortage monitoring processes, and submit requests for specific acquisitions. | Cancer
> Cancer: most types | Pricing and affordability advocacy
> Tracking and monitoring drug pricing/drug shortages | 100,000 | Regional | Regularly | 119078608825 |
| We participate in medicine supply committees. | HIV
> HIV | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 5,000 | Local | Sometimes | 119013267866 |
| Some 95% of the patients who comprise of our target population rely on public health services. | Not specified
> Not specified | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 100 | National | Regularly | 119063173812 |
| We work to ensure that patients receive the treatment they require. | Rare
> Rare diseases: metabolic/lysosomal | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 1,000 | National | Sometimes | 119074171364 |
| … The Federation takes part in meetings, consultations, and collaborative projects aimed at strengthening timely access to medicines and innovative therapies for the community. | Bleeding
> Haemophilia | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 1,000 | National | Sometimes | 119076498939 |
| We support public health sector hospitals in Mexico when they lack access to medicines, diagnostic services, or prostheses. | Cancer
> Cancer: children’s / young people’s | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 5,000 | Regional | Sometimes | 119078492059 |
| We support public health sector hospitals in Mexico when they lack access to medicines, diagnostic services, or prostheses. | Cancer
> Cancer: children’s / young people’s | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 5,000 | Regional | Sometimes | 119078492059 |
| The Federation participates in dialogue and collaboration forums with institutions within Mexico's healthcare system — including IMSS [Instituto Mexicano del Seguro Social – Mexican Social Security Institute], ISSSTE [Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado – Institute for Social Security and Services for State Workers], and other health authorities — to give voice to the needs of people living with coagulation disorders.Through these collaborative efforts, patient experiences are shared, barriers to treatment access are identified, and improvements to care models are promoted. | Bleeding
> Haemophilia | Evidence-based patient input
> Leverage patient stories and lived-experience narratives | 1,000 | National | Sometimes | 119076498939 |
| We participate in forums with authorities, representing the patient voice. | Rare
> Rare disorders: genetic | Institutional governance
> Ensure representation within governmental advisory bodies | 100 | National | Sometimes | 119074314899 |
| The Federation participates in dialogue and collaboration forums with institutions within Mexico's healthcare system — including IMSS [Instituto Mexicano del Seguro Social – Mexican Social Security Institute], ISSSTE [Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado – Institute for Social Security and Services for State Workers], and other health authorities — to give voice to the needs of people living with coagulation disorders. | Bleeding
> Haemophilia | Institutional governance
> Ensure representation within governmental advisory bodies | 1,000 | National | Sometimes | 119076498939 |
| We participate in forums with authorities, representing the patient voice, and we also convene stakeholders to engage in these discussions. | Rare
> Rare disorders: genetic | Institutional governance
> Working effectively within multi-stakeholder networks | 100 | National | Sometimes | 119074314899 |
| The Federation participates in dialogue and collaboration forums with institutions within Mexico's healthcare system — including IMSS [Instituto Mexicano del Seguro Social – Mexican Social Security Institute], ISSSTE [Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado – Institute for Social Security and Services for State Workers], and other health authorities — to give voice to the needs of people living with coagulation disorders. | Bleeding
> Haemophilia | Institutional governance
> Working effectively within multi-stakeholder networks | 1,000 | National | Sometimes | 119076498939 |
interactions
actions & advocacy
6 mentions
